The trastuzumab for gastric cancer (ToGA) trial was a clinical phase 3 trial that compared the HER2 monoclonal antibody (trastuzumab) plus chemotherapy with chemotherapy alone for treating HER2-positive advanced gastric or gastroesophageal junction cancer. The gene discussed is ERBB2; the disease is gastric cancer.